Last updated: February 13, 2026
Overview of NDC 76385-0131
NDC 76385-0131 is identified as Ruxolitinib (generic name), approved for treatment of myelofibrosis, polycythemia vera, and certain cases of graft-versus-host disease (GVHD). Manufactured by Incyte Corporation, this drug's marketed version is Jakafi. It is a JAK1/JAK2 inhibitor with a significant market presence in hematology-oncology.
Current Market Context
- Approved Indications: Myelofibrosis, polycythemia vera, steroid-refractory acute and chronic GVHD.
- Market Penetration: Jakafi ranked as the leading drug for myelofibrosis with over $1.5 billion in annual sales in 2022.
- Market Exclusivity: Patent protections extend until at least 2028, with potential for additional exclusivity via formulations or new indications.
Market Dynamics
| Factor |
Impact |
| Competitive landscape: |
Minimal direct competition; some JAK inhibitors like fedratinib exist. |
| Pricing strategy: |
Retails around $11,000–$13,000 per month, depending on dosage and patient insurance coverage. |
| Reimbursement conditions: |
Favorable due to serious indications; prior authorization burdens are common. |
| Patient populations: |
Estimated at 15,000–20,000 U.S. patients annually for approved uses. |
Market Size and Penetration
The U.S. market has roughly 12,000–15,000 eligible patients for myelofibrosis, and about 2,000–3,000 for polycythemia vera. The penetrance of Jakafi menus estimates that approximately 60% of eligible patients are treated, driven by physician adoption and insurance coverage.
Pricing Projections
Current Pricing Trends
- Average wholesale price (AWP): ~$13,000 per month, translating to ~$156,000 annually.
- Net prices (post discounts): Estimated at 75–85% of AWP, with insurance rebates.
Future Price Trends (2023–2028)
- Inflation adjustments: Historically, prices have increased 2–4% annually.
- Potential for price stabilizations: Due to increasing biosimilar competition and generic development, especially after patent expiration.
| Year |
Projected Annual Price (USD) |
Notes |
| 2023 |
$155,000–$165,000 |
Current pricing with minor adjustments. |
| 2024 |
$160,000–$170,000 |
Slight increase expected. |
| 2025 |
$165,000–$175,000 |
Possible introduction of biosimilars. |
| 2026 |
$160,000–$172,000 |
Price stabilization with biosimilar competition. |
| 2027 |
$150,000–$165,000 |
Patent expiry pending; biosimilars may affect price. |
Competitive Threats and Impact
- Biosimilars: Expected launch by 2028, potentially reducing prices 20–30%.
- New Indications: Expanded use might sustain revenue despite competition.
- Regulatory developments: Additional indications or formulations could sustain higher prices.
Regulatory and Patent Considerations
- Patent expiry: Encyte’s patent protections for Jakafi expire around 2028, increasing risk of biosimilar entry.
- Orphan drug exclusivity: Protects certain indications until 2023–2024 but unlikely to block biosimilars.
Key Takeaways
- NDC 76385-0131 (Ruxolitinib/Jakafi) commands a high price due to serious indications and market exclusivity.
- The market size remains limited but lucrative, supporting prices around $13,000/month currently.
- Price projections indicate stability through 2025, with potential declines post-2028 due to biosimilar competition.
- Market dynamics are influenced by patent protections, new indications, and emerging biosimilars.
FAQs
1. How does biosimilar competition affect Jakafi pricing?
Biosimilars are expected to enter the market around 2028, likely leading to a 20–30% price decrease due to increased competition.
2. Are there off-label uses that could expand the market?
Yes. Some exploratory studies and approvals for GVHD have expanded the use, but these are not the primary indications and have limited impact on overall revenue estimates.
3. What are the major barriers to price reduction?
High treatment cost is justified by the severity of indications, limited competition, and patent protections until at least 2028.
4. What role does insurance reimbursement play?
Insurance reimbursement stabilizes revenue streams but can influence net price through negotiated discounts and prior authorization.
5. How do regulatory changes influence future markets?
Approval of new indications or expanded labeling can sustain or boost market size; regulatory delays or restrictions could constrain growth.
Citations
[1] Incyte Corporation. Jakafi (ruxolitinib) prescribing information, 2023.
[2] EvaluatePharma, 2023. Oncology market analysis.
[3] IQVIA, 2022. U.S. drug sales and utilization data.
[4] FDA, 2023. Patent and exclusivity data for Jakafi.
